Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 150 No. 3334 (2020)

Beta-blocker use and up-titration after acute ST-segment elevation myocardial infarction: a cohort study

DOI
https://doi.org/10.4414/smw.2020.20321
Cite this as:
Swiss Med Wkly. 2020;150:w20321
Published
18.08.2020

Summary

BACKGROUND

The European Society of Cardiology recommends beta-blocker prescription after ST-segment elevation myocardial infarction (STEMI). Evidence for beta-blocker indication depends on the presence of left ventricular dysfunction (left ventricular ejection fraction [LVEF] <40%, class I level A; LVEF ≥40%, class IIa level B). In clinical practice, beta-blockers should be up-titrated to target doses as long as patients tolerate them. The aim of this study was to assess the patterns of beta-blocker prescription and up-titration after STEMI for one year after hospital discharge.

METHODS

This observational study included patients admitted to a tertiary hospital for STEMI between April 2014 and April 2016. Patients with beta-blocker contraindications were excluded from the study. The primary outcomes were the patterns of beta-blocker prescription at discharge and at one year post-PCI, and the evolution of beta-blocker doses over the year. Beta-blocker doses were classified as low (<50% of the target dose) or high (≥50% target). As secondary outcomes, we assessed whether the beta-blocker prescriptions were different according to the type of hospital (university vs district) the patients were discharged from, and whether a short length of stay during the index event was related to a poor beta-blocker prescription at one year post-PCI.

RESULTS

Overall, 266 patients were followed for one year. Of the 217 patients with LVEF ≥40%, 197 (90.8%) received beta-blocker prescriptions at hospital discharge. At the time of discharge, doses were high for 13 (6.0%) and low for 184 (84.8%) patients. In the latter group, nine (4.9%) doses were up-titrated to high during the year after STEMI. Of the 49 patients with LVEFs <40%, 46 (93.9%) received beta-blocker prescriptions at discharge. Doses were high for 3 (6.1%) and low for 43 (87.8%) patients. In the latter group, two (4.7%) doses were up-titrated to high during the year after STEMI. Patients transferred to district hospitals were more likely to have no beta-blocker prescription at discharge in both LVEF groups. Finally, patients without any beta-blocker prescription at one year were more likely to have had a short university hospital stay during the index event.

CONCLUSION

Beta-blocker prescription after STEMI remains prevalent, but most doses are low and up-titration within one year is rare. This raises concern, particularly for patients with LVEFs <40%. Our findings highlight the changes in clinical practice over the last few decades, which corroborate with the latest evidence-based findings.

References

  1. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247(12):1707–14. doi:.https://doi.org/10.1001/jama.1982.03320370021023
  2. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Nyberg G, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;318(8251):823–7. doi:.https://doi.org/10.1016/S0140-6736(81)91101-6
  3. Herlitz J, Elmfeldt D, Hjalmarson A, Holmberg S, Málek I, Nyberg G, et al. Effect of metoprolol on indirect signs of the size and severity of acute myocardial infarction. Am J Cardiol. 1983;51(8):1282–8. doi:.https://doi.org/10.1016/0002-9149(83)90299-0
  4. Snow PJ. Effect of propranolol in myocardial infarction. Lancet. 1965;286(7412):551–3. doi:.https://doi.org/10.1016/S0140-6736(65)90863-9
  5. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77. doi:.https://doi.org/10.1093/eurheartj/ehx393
  6. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr, Chung MK, de Lemos JA, et al., American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–425. doi:.https://doi.org/10.1161/CIR.0b013e3182742c84
  7. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90. doi:.https://doi.org/10.1016/S0140-6736(00)04560-8
  8. Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-Analysis of Relation Between Oral β-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. Am J Cardiol. 2015;115(11):1529–38. doi:.https://doi.org/10.1016/j.amjcard.2015.02.057
  9. De Luca G, de Boer MJ, Ottervanger JP, van ’t Hof AW, Hoorntje JC, Gosselink AT, et al. Impact of beta-blocker therapy at discharge on long-term mortality after primary angioplasty for ST-segment elevation myocardial infarction. Am J Cardiol. 2005;96(6):806–9. doi:.https://doi.org/10.1016/j.amjcard.2005.05.025
  10. Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O’Neill WW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol. 2004;43(10):1773–9. doi:.https://doi.org/10.1016/j.jacc.2003.09.071
  11. Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, et al.; Osaka Acute Coronary Insufficiency Study (OACIS) Investigators. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. Am J Cardiol. 2013;111(4):457–64. doi:.https://doi.org/10.1016/j.amjcard.2012.10.026
  12. Rydén L, Ariniego R, Arnman K, Herlitz J, Hjalmarson A, Holmberg S, et al. A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med. 1983;308(11):614–8. doi:.https://doi.org/10.1056/NEJM198303173081102
  13. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al.; OBTAIN Investigators. Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. J Am Coll Cardiol. 2015;66(13):1431–41. doi:.https://doi.org/10.1016/j.jacc.2015.07.047
  14. Allen JE, Knight S, McCubrey RO, Bair T, Muhlestein JB, Goldberger JJ, et al. β-blocker dosage and outcomes after acute coronary syndrome. Am Heart J. 2017;184:26–36. doi:.https://doi.org/10.1016/j.ahj.2016.10.012
  15. Barron HV, Viskin S, Lundstrom RJ, Swain BE, Truman AF, Wong CC, et al. Beta-blocker dosages and mortality after myocardial infarction: data from a large health maintenance organization. Arch Intern Med. 1998;158(5):449–53. doi:.https://doi.org/10.1001/archinte.158.5.449
  16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. doi:.https://doi.org/10.1093/eurheartj/ehw128
  17. Auer R, Gencer B, Räber L, Klingenberg R, Carballo S, Carballo D, et al. Quality of care after acute coronary syndromes in a prospective cohort with reasons for non-prescription of recommended medications. PLoS One. 2014;9(3):e93147. doi:.https://doi.org/10.1371/journal.pone.0093147
  18. Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O’Rourke R, et al.; PACE-MI Investigators. beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am Heart J. 2010;160(3):435–442.e1. doi:.https://doi.org/10.1016/j.ahj.2010.06.023
  19. Gislason GH, Rasmussen JN, Abildstrøm SZ, Gadsbøll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153–8. doi:.https://doi.org/10.1093/eurheartj/ehi705
  20. Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? J Am Coll Cardiol. 2017;69(20):2542–50. doi:.https://doi.org/10.1016/j.jacc.2017.03.563
  21. Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol. 2013;62(19):1791–801. doi:.https://doi.org/10.1016/j.jacc.2013.04.102
  22. U.S. National Library of Medicine. Evaluation of decreased usage of Betablockers after myocardial infarction in the SWEDEHEART registry (REDUCE-SWEDEHEART). https://clinicaltrials.gov/ct2/show/NCT03278509?term=03278509&draw=2&rank=1. Accessed 2019 November 4.
  23. U.S. National Library of Medicine. Betablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function (BETAMI). https://clinicaltrials.gov/ct2/show/NCT03646357?term=03646357&draw=2&rank=1. Accessed 2019 November 4.
  24. Peikes D, Chen A, Schore J, Brown R. Effects of care coordination on hospitalization, quality of care, and health care expenditures among Medicare beneficiaries: 15 randomized trials. JAMA. 2009;301(6):603–18. doi:.https://doi.org/10.1001/jama.2009.126
  25. Ziemer DC, Doyle JP, Barnes CS, Branch WT, Jr, Cook CB, El-Kebbi IM, et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving Primary Care of African Americans with Diabetes (IPCAAD) 8. Arch Intern Med. 2006;166(5):507–13. doi:.https://doi.org/10.1001/archinte.166.5.507

Most read articles by the same author(s)

<< < 1 2